Status:
UNKNOWN
Mucosal Immunity in Terms of SARS-CoV-2 Antibodies in Saliva After COVID-19 Infection and Vaccination
Lead Sponsor:
Lenanrt Friis-Hansen
Conditions:
Covid19
Eligibility:
All Genders
18+ years
Brief Summary
The Primary Objective of This Single-center Study is to Investigate the SARS-CoV-2 Spike Glycoprotein RBD Antibody Concentration in Saliva and Serum in Healthy Non Vaccinated and Non-SARS-CoV-2 Infect...
Eligibility Criteria
Inclusion
- Written informed consent
- Both Hospital staff as well as non-health care workers will be invited to participate
Exclusion
- Individuals not fulfilling the inclusion criteria or declining blood or saliva collection.
- Exclusion criteria are neck breathers (tracheostomy/laryngectomy patients) or other nasopharyngeal or oropharyngeal anomalies that do not allow for sampling using Salivette.
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 15 2024
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04842305
Start Date
April 1 2021
End Date
March 15 2024
Last Update
April 13 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.